AAAAAA

   
Results: 1-25 |
Results: 25
Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes
Authors: Slingluff, CL Yamshchikov, G Neese, P Galavotti, H Eastham, S Engelhard, VH Kittlesen, D Deacon, D Hibbitts, S Grosh, WW Petroni, G Cohen, R Wiernasz, C Patterson, JW Conway, BP Ross, WG
Citation: Cl. Slingluff et al., Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes, CLIN CANC R, 7(10), 2001, pp. 3012-3024
Identification and modulation of a naturally processed T cell epitope fromthe diabetes-associated autoantigen human glutamic acid decarboxylase 65 (hGAD65)
Authors: Nepom, GT Lippolis, JD White, FM Masewicz, S Marto, JA Herman, A Luckey, CJ Falk, B Shabanowitz, J Hunt, DF Engelhard, VH Nepom, BS
Citation: Gt. Nepom et al., Identification and modulation of a naturally processed T cell epitope fromthe diabetes-associated autoantigen human glutamic acid decarboxylase 65 (hGAD65), P NAS US, 98(4), 2001, pp. 1763-1768
Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model, (vol 97, pg 297, 2000)
Authors: Arichi, T Saito, T Major, ME Belyakov, IM Shirai, M Engelhard, VH Feinstone, SM Berzofsky, JA
Citation: T. Arichi et al., Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model, (vol 97, pg 297, 2000), P NAS US, 98(10), 2001, pp. 5943-5943
Immune responses to the HLA-A0201-restricted epitopes of tyrosinase and glycoprotein 100 enable control of melanoma outgrowth in HLA-A*0201-transgenic mice
Authors: Mullins, DW Bullock, TNJ Colella, TA Robila, VV Engelhard, VH
Citation: Dw. Mullins et al., Immune responses to the HLA-A0201-restricted epitopes of tyrosinase and glycoprotein 100 enable control of melanoma outgrowth in HLA-A*0201-transgenic mice, J IMMUNOL, 167(9), 2001, pp. 4853-4860
The HA-2 minor histocompatibility antigen is derived from a diallelic geneencoding a novel human class I myosin protein
Authors: Pierce, RA Field, ED Mutis, T Golovina, TN Von Kap-Herr, C Wilke, M Pool, J Shabanowitz, J Pettenati, MJ Eisenlohr, LC Hunt, DF Goulmy, E Engelhard, VH
Citation: Ra. Pierce et al., The HA-2 minor histocompatibility antigen is derived from a diallelic geneencoding a novel human class I myosin protein, J IMMUNOL, 167(6), 2001, pp. 3223-3230
Differences in the expression of human class I MHC alleles and their associated peptides in the presence of proteasome inhibitors
Authors: Luckey, CJ Marto, JA Partridge, M Hall, E White, FM Lippolis, JD Shabanowitz, J Hunt, DF Engelhard, VH
Citation: Cj. Luckey et al., Differences in the expression of human class I MHC alleles and their associated peptides in the presence of proteasome inhibitors, J IMMUNOL, 167(3), 2001, pp. 1212-1221
Manipulation of avidity to improve effectiveness of adoptively transferredCD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice
Authors: Bullock, TNJ Mullins, DW Colella, TA Engelhard, VH
Citation: Tnj. Bullock et al., Manipulation of avidity to improve effectiveness of adoptively transferredCD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice, J IMMUNOL, 167(10), 2001, pp. 5824-5831
The immunogenicity of a new human minor histocompatibility antigen resultsfrom differential antigen processing
Authors: Brickner, AG Warren, EH Caldwell, JA Akatsuka, Y Golovina, TN Zarling, AL Shabanowitz, J Eisenlohr, LC Hunt, DF Engelhard, VH Riddell, SR
Citation: Ag. Brickner et al., The immunogenicity of a new human minor histocompatibility antigen resultsfrom differential antigen processing, J EXP MED, 193(2), 2001, pp. 195-205
Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients
Authors: Yamshchikov, GV Barnd, DL Eastham, S Galavotti, H Patterson, JW Deacon, DH Teates, D Neese, P Grosh, WW Petroni, G Engelhard, VH Slingluff, GL
Citation: Gv. Yamshchikov et al., Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients, INT J CANC, 92(5), 2001, pp. 703-711
Identification of endogenous peptides recognized by in vivo or in vitro generated alloreactive cytotoxic T lymphocytes: distinct characterictics correlated with CD8 dependence (vol 31, pg 421, 2001)
Authors: Guimezanes, A Barrett-Wilt, GA Gulden-Thompson, P Shabanowitz, J Engelhard, VH Hunt, DF Schmitt-Verhulst, AM
Citation: A. Guimezanes et al., Identification of endogenous peptides recognized by in vivo or in vitro generated alloreactive cytotoxic T lymphocytes: distinct characterictics correlated with CD8 dependence (vol 31, pg 421, 2001), EUR J IMMUN, 31(4), 2001, pp. 1298-1298
Tyrosinase degradation via two pathways during reverse translocation to the cytosol
Authors: Mosse, CA Hsu, W Engelhard, VH
Citation: Ca. Mosse et al., Tyrosinase degradation via two pathways during reverse translocation to the cytosol, BIOC BIOP R, 285(2), 2001, pp. 313-319
Determination of intronic sequences adjacent to an exon using polymerase chain reaction and genomic DNA library constructed by TA cloning
Authors: Akatsuka, Y Warren, EH Brickner, AG Engelhard, VH Riddell, SR
Citation: Y. Akatsuka et al., Determination of intronic sequences adjacent to an exon using polymerase chain reaction and genomic DNA library constructed by TA cloning, ANALYT BIOC, 289(2), 2001, pp. 289-292
Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use
Authors: Engelhard, VH Bullock, TNV Colella, TA Mullins, DW
Citation: Vh. Engelhard et al., Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use, CANCER J, 6, 2000, pp. S272-S280
Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens
Authors: Slingluff, CL Colella, TA Thompson, L Graham, DD Skipper, JCA Caldwell, J Brinckerhoff, L Kittlesen, DJ Deacon, DH Oei, C Harthun, NL Huczko, EL Hunt, DF Darrow, TL Engelhard, VH
Citation: Cl. Slingluff et al., Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens, CANCER IMMU, 48(12), 2000, pp. 661-672
Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model
Authors: Arichi, T Saito, T Major, ME Belyakov, IM Shirai, M Engelhard, VH Feinstone, SM Berzofsky, JA
Citation: T. Arichi et al., Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model, P NAS US, 97(1), 2000, pp. 297-302
The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice
Authors: Bullock, TNJ Colella, TA Engelhard, VH
Citation: Tnj. Bullock et al., The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice, J IMMUNOL, 164(5), 2000, pp. 2354-2361
Immunodominance among EBV-derived epitopes restricted by HLA-B27 does not correlate with epitope abundance in EBV-transformed B-lymphoblastoid cell lines
Authors: Crotzer, VL Christian, RE Brooks, JM Shabanowitz, J Settlage, RE Marto, JA White, FM Rickinson, AB Hunt, DF Engelhard, VH
Citation: Vl. Crotzer et al., Immunodominance among EBV-derived epitopes restricted by HLA-B27 does not correlate with epitope abundance in EBV-transformed B-lymphoblastoid cell lines, J IMMUNOL, 164(12), 2000, pp. 6120-6129
Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo
Authors: Zarling, AL Ficarro, SB White, FM Shabanowitz, J Hunt, DF Engelhard, VH
Citation: Al. Zarling et al., Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo, J EXP MED, 192(12), 2000, pp. 1755-1762
Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: Implications for tumor immunotherapy
Authors: Colella, TA Bullock, TNJ Russell, LB Mullins, DW Overwijk, WW Luckey, CJ Pierce, RA Restifo, NP Engelhard, VH
Citation: Ta. Colella et al., Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: Implications for tumor immunotherapy, J EXP MED, 191(7), 2000, pp. 1221-1231
Pseudomonas exotoxin-mediated delivery of exogenous antigens to MHC class I and class II processing pathways
Authors: Lippolis, JD Denis-Mize, KS Brinckerhoff, LH Slingluff, CL Galloway, DR Engelhard, VH
Citation: Jd. Lippolis et al., Pseudomonas exotoxin-mediated delivery of exogenous antigens to MHC class I and class II processing pathways, CELL IMMUN, 203(2), 2000, pp. 75-83
Cutting edge: The HLA-A0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique
Authors: Pierce, RA Field, ED den Haan, JMM Caldwell, JA White, FM Marto, JA Wang, W Frost, LM Blokland, E Reinhardus, C Shabanowitz, J Hunt, DF Goulmy, E Engelhard, VH
Citation: Ra. Pierce et al., Cutting edge: The HLA-A0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique, J IMMUNOL, 163(12), 1999, pp. 6360-6364
Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumor vaccine development (vol 160, pg 2099, 1998)
Authors: Kittlesen, DJ Thompson, LW Gulden, PH Skipper, JCA Colella, TA Shabanowitz, J Hunt, DF Engelhard, VH Slingluff, CL
Citation: Dj. Kittlesen et al., Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumor vaccine development (vol 160, pg 2099, 1998), J IMMUNOL, 162(5), 1999, pp. 3106-3106
A naturally processed peptide presented by HLA-A0201 is expressed at low abundance and recognized by an alloreactive CD8(+) cytotoxic T cell with apparent high affinity (vol 158, pg 5797, 1997)
Authors: Wang, W Gulden, PH Pierce, RA Shabanowitz, JA Man, ST Hunt, DF Engelhard, VH
Citation: W. Wang et al., A naturally processed peptide presented by HLA-A0201 is expressed at low abundance and recognized by an alloreactive CD8(+) cytotoxic T cell with apparent high affinity (vol 158, pg 5797, 1997), J IMMUNOL, 162(5), 1999, pp. 3106-3106
Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: Implications for peptide vaccines
Authors: Brinckerhoff, LH Kalashnikov, VV Thompson, LW Yamshchikov, GV Pierce, RA Galavotti, HS Engelhard, VH Slingluff, CL
Citation: Lh. Brinckerhoff et al., Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: Implications for peptide vaccines, INT J CANC, 83(3), 1999, pp. 326-334
Mass-spectrometric evaluation of HLA-A0201-associated peptides identifiesdominant naturally processed forms of CTL epitopes from MART-1 and gp100
Authors: Skipper, JCA Gulden, PH Hendrickson, RC Harthun, N Caldwell, JA Shabanowitz, J Engelhard, VH Hunt, DF Slingluff, CL
Citation: Jca. Skipper et al., Mass-spectrometric evaluation of HLA-A0201-associated peptides identifiesdominant naturally processed forms of CTL epitopes from MART-1 and gp100, INT J CANC, 82(5), 1999, pp. 669-677
Risultati: 1-25 |